These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 38979994)
1. A consensus survey of neurologists and clinical geneticists on spinal muscular atrophy treatment in Singapore. Lim JYX; Wang FS; Ling SR; Tay SKH Ann Acad Med Singap; 2024 Jun; 53(6):386-389. PubMed ID: 38979994 [No Abstract] [Full Text] [Related]
2. Cost-Effectiveness of Onasemnogene Abeparvovec Compared With Nusinersen and Risdiplam in Patients With Spinal Muscular Atrophy Type 1 in Brazil: Custo-Efetividade do Onasemnogeno Abeparvoveque (AVXS-101) em Comparação ao Nusinersena e Risdiplam em Pacientes com Atrofia Muscular Espinhal Tipo 1 no Brasil. Fernandes BD; D'Athayde Rodrigues F; Cardoso Cirilo HN; Borges SS; Krug BC; Probst LF; Zimmermann I Value Health Reg Issues; 2024 Mar; 40():108-117. PubMed ID: 38181723 [TBL] [Abstract][Full Text] [Related]
3. Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis. Toro W; Yang M; Georgieva M; Song W; Patel A; Jiang AX; Zhao A; LaMarca N; Dabbous O Adv Ther; 2023 Oct; 40(10):4589-4605. PubMed ID: 37587305 [TBL] [Abstract][Full Text] [Related]
4. Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study. Bitetti I; Lanzara V; Margiotta G; Varone A Gene Ther; 2023 Aug; 30(7-8):592-597. PubMed ID: 35606491 [TBL] [Abstract][Full Text] [Related]
5. [Recommendations for gene therapy of spinal muscular atrophy with onasemnogene abeparvovec-AVXS-101 : Consensus paper of the German representatives of the Society for Pediatric Neurology (GNP) and the German treatment centers with collaboration of the medical scientific advisory board of the German Society for Muscular Diseases (DGM)]. Ziegler A; Wilichowski E; Schara U; Hahn A; Müller-Felber W; Johannsen J; von der Hagen M; von Moers A; Stoltenburg C; Saffari A; Walter MC; Husain RA; Pechmann A; Köhler C; Horber V; Schwartz O; Kirschner J Nervenarzt; 2020 Jun; 91(6):518-529. PubMed ID: 32394004 [TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Technologies for the Treatment of Spinal Muscular Atrophy: A Systematic Review of Economic Studies. Motta-Santos A; Noronha K; Reis C; Freitas D; Carvalho L; Andrade M Value Health Reg Issues; 2024 Jul; 42():100985. PubMed ID: 38669792 [TBL] [Abstract][Full Text] [Related]
8. How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison. Ribero VA; Daigl M; Martí Y; Gorni K; Evans R; Scott DA; Mahajan A; Abrams KR; Hawkins N J Comp Eff Res; 2022 Apr; 11(5):347-370. PubMed ID: 35040693 [No Abstract] [Full Text] [Related]
9. [Spinal muscular atrophy]. Martin P; Horber V; Park J; Kronlage C; Grimm A Nervenarzt; 2022 Feb; 93(2):191-200. PubMed ID: 35037967 [TBL] [Abstract][Full Text] [Related]
16. Safety Concerns with Nusinersen, Risdiplam, and Onasemnogene Abeparvovec in Spinal Muscular Atrophy: A Real-World Pharmacovigilance Study. Zhuang W; Lu M; Wu Y; Chen Z; Wang M; Wang X; Guan S; Lin W Clin Drug Investig; 2023 Dec; 43(12):949-962. PubMed ID: 37995087 [TBL] [Abstract][Full Text] [Related]